Donor antigen–presenting cells are important in the development of obliterative airway disease  by Szeto, Wilson Y. et al.
Lung transplantation has become a widely acceptedform of therapy for end-stage lung disease, with
approximately 10,000 lung transplantation procedures
performed throughout the world.1 As a result of
improvements in surgical techniques and immunosup-
pression, the short-term survival after lung transplanta-
tion has improved dramatically, with 1-year survival
currently approaching 70%.1 However, the current 5-
year survival is 43.3% with a median survival of 3.7
years.1 Long-term survival in lung transplantation has
been limited primarily by the development of oblitera-
tive bronchiolitis (OB). The incidence of OB is 28% at
1 year after transplantation and reaches 60% to 80%
after 5 to 10 years.2,3 OB is characterized by a fibropro-
liferative process that predominately involves the small-
er airways. Histologic features include luminal obliter-
ation of the airway accompanied by lymphocytic
infiltrates and epithelial desquamation and necrosis.4
Objective: Obliterative airway disease, which resembles obliterative bronchi-
olitis histologically, develops in murine heterotopic tracheal allografts.
Chimeric tracheas were used to examine whether donor-type antigen-pre-
senting cells are important in the development of obliterative airway disease.
To separate the contributions of CD4+ and CD8+ direct pathways, we trans-
planted tracheas from knockout mice lacking major histocompatibility com-
plex (MHC) class I or II antigens. 
Methods: Chimeric tracheas were created via bone marrow transplantation in
fully MHC-mismatched combinations. Tracheas from naive B6, autologous-
ly reconstituted B6, chimeric B6 bearing recipient-type C3H antigen-pre-
senting cells, MHC class I knockout B6 (B6I–), MHC class II knockout B6
(B6II–), or C3H mice were transplanted into C3H recipients. The tracheas
were harvested at days 14 and 28.
Results: At day 28, isografts showed no occlusion, normal respiratory epithe-
lium, and minimal infiltrates. Naive or autologously reconstituted B6, B6I–,
and B6II– tracheas showed minimal occlusion at day 14 but contained
intraepithelial infiltrates. By day 28, the naive or autologously reconstituted
B6 tracheas had occlusion of 69.5% ± 11.6% (mean ± standard error of the
mean), and in comparison, B6I– and B6II– tracheas had occlusions of 53.0%
± 16.3% and 52.2% ± 15.9%, respectively (P = .20, .19). In chimeric B6 tra-
cheas, minimal occlusion was seen at day 14 and remained 33.6% ± 16.2%
(P = .039) at day 28. Subtle epithelial changes and minimal infiltrates were
seen.
Conclusions: Obliterative airway disease appears to involve donor-type anti-
gen-presenting cells and develops in the absence of either MHC class I or II
antigens. These findings suggest that either CD8+ or CD4+ direct allorecog-
nition is important in the development of obliterative airway disease. 
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The pathogenesis of OB remains poorly understood,
but the histologic characteristics and the absence of the
process in experimental animals rendered tolerant have
led many to speculate that OB is the primary manifes-
tation of chronic rejection in lung transplantation.
Clinical observations support the notion that OB results
from alloimmune-mediated mechanisms. Acute rejec-
tion has been demonstrated to be a major risk factor for
the subsequent development of OB.5-7 Up-regulation of
major histocompatibility complex (MHC) class I and
class II antigens on bronchial epithelium and infiltra-
tion of donor-specific lymphocyte subsets have been
found in grafts with OB.8-10 The presence of anti-HLA
class I antibodies in lung transplant recipients is asso-
ciated with OB, and recently anti-HLA class I antibod-
ies have been shown to lead to protein phosphorylation
and proliferation of cultured lung epithelium.11
Furthermore, increased immunosuppression has been
shown to stabilize lung function in some patients.12,13
Bone marrow–derived antigen-presenting cells
(APCs) play a central role in triggering recipient T
cells.14 However, little is known about how allorecog-
nition pathways affect the development of OB.
Responses to allogeneic tissue are unique in that both
donor and recipient APCs are capable of triggering
rejection, termed direct and indirect allorecognition,
respectively. Both recipient CD4+ and CD8+ T cells can
be triggered directly by donor APCs, whereas recipient
APCs stimulate only CD4+ T cells by presenting
allopeptides in the context of self MHC class II mole-
cules. Understanding the role of allorecognition path-
ways in OB may lead to the development of rational
strategies to prevent this malady.
The goal of our study was to investigate whether
direct allorecognition triggered by donor APCs is
important in the development of OB, and, if so, which
pathways are involved. We used a heterotopic mouse
tracheal transplant model to study the development of
obliterative airway disease, which resembles OB histo-
logically.15 To eliminate the direct allorecognition
pathway, we created chimeric B6 tracheas bearing
recipient C3H APCs, denoted hereafter as B6(C3H),
using allogeneic bone marrow transplantation
(BMT),16,17 and transplanted them into C3H recipi-
ents. Furthermore, tracheas from B6 MHC class I
knockout (B6I–) mice and B6 MHC class II knockout
(B6II–) mice were transplanted to examine the contri-
butions of CD4+ and CD8+ direct allorecognition path-
ways. Naive or autologously reconstituted B6 and C3H
tracheas were transplanted into C3H recipients as our
positive and negative controls, respectively. The autol-
ogously reconstituted B6 tracheas, denoted hereafter
as B6(B6), behaved similarly to the naive B6 and
served as controls for the BMT tracheas. We report
here that donor bone marrow–derived APCs are impor-
tant in the development of obliterative airway disease
and that donor APC expression of either MHC class I
or class II antigen is sufficient to trigger the develop-
ment of obliterative airway disease.
Materials and methods
Experimental animals. All laboratory animals received
humane care in compliance with the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources and published by the National
Institutes of Health (NIH Publication No. 86-23, revised
1985). All animals were housed in conventional cages with
filter lids and provided access to food and water. Donor
C57BL/6 (B6, H-2b), MHC class I knockout (ß2m deficient)
on the C57/BL6 background (B6I–) mice, and MHC class II
knockout (I-Ab ß-chain deficient) on the C57/BL6 back-
ground (B6II–) mice, 5 to 7 weeks of age, were purchased
from Taconic Laboratories (Germantown, NY). C3H/HeJ (H-
2k) mice, 5 to 7 weeks of age, were purchased from Jackson
Laboratory (Bar Harbor, Maine).
BMT. Chimeric tracheas were created by BMT as previ-
ously described.16,17 In brief, BMT recipient mice were
lethally irradiated (10 Gy) and then reconstituted with 1 × 107
unfractionated bone marrow cells from a donor, injected in 1
mL of medium via the tail vein. The BMT recipients were
treated with 2 weeks of oral antibiotics and allowed to engraft
for 90 days before their use as trachea donors.
Heterotopic tracheal transplantation. By means of a
technique first described by Hertz and associates,15 1 to 4 tra-
cheal segments were transplanted subcutaneously into the
dorsa of C3H recipients in experimental groups as shown in
Table I. Recipients with multiple tracheal segments contained
grafts from the same genotypes. No immunosuppression was
administered to any group. Donor mice were anesthetized
with enflurane, and their skin was prepared with ethyl alco-
hol. In each case, the thoracic cavity was entered through a
midline incision, and the animal was exsanguinated. The thy-
mus and the heart were removed, so that the trachea and the
main bronchi were exposed. With sharp dissection, the tra-
chea from the larynx to the carina was removed and placed in
cold Dulbecco’s phosphate-buffered saline solution (Gibco,
Grand Island, NY).
Recipient mice were similarly anesthetized, and their
dorsa were shaved and prepared with ethyl alcohol. A small
skin incision was made on their dorsa and the tracheal seg-
ments were implanted subcutaneously. The incision was
closed with 4-0 Vicryl sutures (Ethicon, Inc, Somerville,
NJ). The time interval between harvest and implantation was
less than 10 minutes. 
Confirmation of chimerism with flow cytometry. To
confirm the status of bone marrow chimeras, we analyzed
flow cytometry as previously described by our laborato-
ry.16,17 We have previously shown that the degree of APC
replacement in the spleen consequent to BMT mirrors the
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degree of APC replacement in other organs. This method has
been further validated by reverse transcriptase–polymerase
chain reaction and the mixed lymphocyte reaction. Spleens
of donor chimeric animals were harvested at the time of
transplantation. The spleens were mechanically disrupted
and filtered over a 70-µm sterile nylon mesh. The spleen
cells were treated with ACK buffer (BioWhittaker,
Walkersville, Md), washed with cold phosphate-buffered
saline solution, and counted. All antibodies were obtained
from Pharmingen (San Diego, Calif). Fluorescein isothio-
cyanate–conjugated mouse anti-mouse I-Ab (clone 25-9-17,
immunoglobulin G2a) and fluorescein isothiocyanate–con-
jugated mouse anti-mouse I-Ak (11-5.2, immunoglobulin
G2b) were used to label spleen cells from chimeras for flow
cytometry analysis. Flow cytometry analysis was performed
on a FACScan flow cytometer equipped with CELLQuest
software (Becton Dickinson, San Jose, Calif). 
Graft removal and data analysis. Tracheal grafts were
removed 14 and 28 days after transplantation. In recipients
with multiple grafts, the tracheal segments were removed at
the same time points. Specimens were fixed in 10% forma-
lin and submitted for staining with hematoxylin and eosin.
All tracheal specimens were evaluated for their degree of
luminal occlusion, the morphology of the respiratory
epithelium, and the presence of intraepithelial and peritra-
cheal cellular infiltrates by a pathologist blinded to the pro-
tocol. For recipients with multiple tracheal segments, the
mean luminal occlusion of the grafts was reported. The
Student t test was used to compare the mean luminal occlu-
sion in all groups versus that of the naive and autologously
reconstituted B6 allograft group.
Results
Confirmation of chimerism. Spleens from all BMT
recipients were analyzed to confirm complete APC
replacement at the time of tracheal harvest for trans-
plantation (data not shown). Tracheas from donors hav-
ing incomplete APC replacement were not included in
this study. 
Luminal occlusion. Luminal occlusion was deter-
mined by microscopy and expressed as a percentage of
the cross-sectional area of the tracheal lumen. The
mean luminal occlusion of the groups was compared as
shown in Fig 1. No statistically significant difference
existed between the mean occlusion of the naive B6
and the autologously reconstituted B6(B6) grafts at day
28 (P = .43). Hence, all B6 and B6(B6) grafts were
placed into the allograft group. At days 14 and 28, none
of the isografts showed evidence of luminal occlusion.
In the allograft group at day 14, the luminal occlusion
was 5.7% ± 5.4% (mean ± standard error of the mean).
Table I. Experimental groups
Tracheal donor Parenchyma APCs Recipient
C3H C3H C3H C3H
B6/B6(B6) B6 B6 C3H
B6(C3H) B6 C3H C3H
B6I– B6I– B6I– C3H
B6II– B6II– B6II– C3H
B6(B6), B6 autologously reconstituted with B6 bone marrow–derived APCs;
B6(C3H), B6 reconstituted with C3H bone marrow–derived APCs; B6I–,
MHC class I antigen knockout B6; B6II–, MHC class II antigen knockout B6. 
Fig 1. The mean luminal occlusion in C3H, B6 and B6(B6), and B6(C3H), B6I–, and B6II– tracheas on days 14 and 28
(n = number of recipients). All tracheas were transplanted into C3H recipients. On day 28, a significant decrease in the
degree of luminal occlusion was noted in the B6(C3H) group compared with the B6 and B6(B6) group (P = .039).
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Fig 2. Photomicrographs of tracheal specimens in cross section stained with hematoxylin and eosin. A and B,
Tracheal sections representative of C3H isografts. A, Isografts are patent with minimal peritracheal inflammation
at day 28 (40×). B, Normal ciliated respiratory epithelium is seen lining the lumen, and intraepithelial lymphocytes
are absent (400×). C to F, Tracheal sections representative of B6, B6(B6), B6I–, and B6II– allografts. At day 14, (C)
the lumina are patent with moderate peritracheal inflammation (40×), and (D) the respiratory epithelium is flat-
tened, nonciliated, and infiltrated with inflammatory cells (400×). At day 28, (E) the allografts are completely
occluded and have minimal peritracheal inflammation (40×); F, the lumina are filled with loose connective tissue
containing scant inflammatory cells, which have replaced the epithelium and submucosal tissue (400×). 
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Specimens from 14 of 15 recipients demonstrated min-
imal occlusion (ranging from 0% to 5%), and 1 of 15
demonstrated marked occlusion (80%). At day 28, the
luminal occlusion was 69.5% ± 11.6%. Specimens
from 10 of 15 recipients demonstrated marked occlu-
sion (ranging from 90% to 100%), and 5 of 15 demon-
strated minimal to moderate occlusion (ranging from
0% to 50%). In the B6I– and B6II– groups, tracheas
showed minimal occlusion at day 14 (ranging from 0%
to 5%). At day 28 in the B6I– group, the luminal occlu-
sion was 53.0% ± 16.3%. Specimens from 4 of 8 recip-
ients demonstrated marked occlusion (ranging from
70% to 100%), and 4 of 8 had moderate occlusion
(ranging from 0% to 55%). Similarly, the luminal
occlusion in the B6II– group at day 28 was 52.2% ±
15.9%. Specimens from 4 of 9 recipients had marked
occlusion (100%), and 5 of 9 demonstrated moderate
occlusion (ranging from 0% to 50%). Tracheas from
the B6I– and B6II– groups did not demonstrate signifi-
cant decreases in luminal occlusion at day 28 when
compared with the allograft group (P = .20, .19, respec-
tively). In the B6(C3H) group at day 14, the luminal
occlusion was 0.7% ± 0.7%. Specimens from all 7
recipients demonstrated minimal occlusion (ranging
from 0% to 5%). At day 28, the luminal occlusion was
33.6% ± 16.2%. Specimens from 6 of 9 recipients
Fig 2. Cont’d. G to J, Tracheal sections representative of B6(C3H) grafts. At day 14, (G) the lumi-
na are patent (40×) and (H) the respiratory epithelium is similar to that seen in allografts; the
epithelium is flattened, nonciliated, and infiltrated with inflammatory cells (400×). At day 28, (I)
the lumina are patent with minimal peritracheal inflammation (40×) and (J) the epithelium remains
intact, although flattened and nonciliated with minimal cellular infiltrates (400×).
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demonstrated minimal occlusion (ranging from 0% to
5%), and 3 of 9 demonstrated marked occlusion (rang-
ing from 90% to 100%). B6(C3H) tracheas demon-
strated a significant decrease in luminal occlusion
when compared with the allograft group at day 28 (P =
.039). 
Epithelial morphology and cellular infiltrates. The
respiratory epithelial morphology, peritracheal inflam-
mation, and intraepithelial cellular infiltrates were
characterized and compared between the groups. In the
isograft group at both days 14 and 28, the respiratory
epithelial lining remained intact and was predominate-
ly ciliated columnar epithelial cells. Minimal to mild
peritracheal inflammation and intraepithelial cellular
infiltrates were seen (Fig 2, A and B). In the B6 and
B6(B6) group at day 14, the respiratory epithelium
remained present, but the cells were predominately flat-
tened and nonciliated. Moderate to severe peritracheal
inflammation and intraepithelial cellular infiltrates
were present (Fig 2, C and D). By day 28, completely
occluded allografts showed no evidence of the respira-
tory epithelium. The amount of peritracheal inflamma-
tion and cellular infiltrates had diminished when com-
pared with the observations on day 14 (Fig 2, E and F).
In the B6(C3H) group at day 14, flattened or atypical,
nonciliated epithelium lined the lumina, much like the
allograft group. Mild to moderate amounts of cellular
infiltrates were seen in the epithelium and the peritra-
cheal tissue. Compared with the allograft group, the
inflammatory events appeared to be slightly diminished
(Fig 2, G and H). Through day 28, flattened or noncil-
iated epithelium persisted in chimeric tracheas with
nonoccluded lumina. Even though peritracheal and
intraepithelial infiltrates persisted, they also appeared
to be diminished when compared with day 14 (Fig 2, I
and J). In both the B6I– and the B6II– groups, the epithe-
lial changes and the severity of cellular infiltrates were
similar to those of the naive and autologously reconsti-
tuted B6 allografts at days 14 and 28.
Discussion
OB is a devastating long-term complication of lung
transplantation, affecting at least 50% of lung trans-
plant recipients surviving beyond 3 years.18 The pro-
gressive decrease in pulmonary function associated
with OB has a profound impact on the quality of life
of these patients, and OB remains the primary cause
of late death after lung transplantation. Currently,
therapeutic options are limited to retransplantation
and intensification of immunosuppression. However,
these strategies have limited success. A better under-
standing of the pathogenesis of OB is necessary if
rational strategies are to be developed for its preven-
tion and treatment.
Evidence from human studies has suggested that OB
is an alloimmune-mediated process against the
bronchial epithelium. Increased immunosuppression
has been shown to stop the progression of OB in some
patients.12,13 Presentation of MHC class I and class II
antigens on the bronchial epithelium has been demon-
strated to be a possible mechanism in the development
of OB.8-11,19-21 Professional APCs such as dendritic
cells are associated with bronchial tissues of patients
with OB and have been postulated to be involved in the
development of OB.22
Animal models have also been described to study the
relationship between the immune responses and the
development of OB. Orthotopic allogeneic lung trans-
plants in rats and pigs develop the lesions of OB.23,24
However, these models require substantial surgical
expertise, and OB does not consistently develop in the
small animal models. The mouse heterotopic tracheal
allograft model of obliterative airway disease was first
described by Hertz and associates15 in 1993. This
model reproduces some of the histopathologic charac-
teristics of OB over a period of 3 to 4 weeks. 
Data from animal studies support the notion that OB
is a result of histoincompatibility. Expression of MHC
class II has been shown to be increased on the
bronchial epithelium in rat lung allografts with OB.23,24
Furthermore, Pham and colleagues25 demonstrated that
induction of tolerance by means of mixed hematopoi-
etic chimerism prevents OB in rat orthotopic lung allo-
grafts. Similarly, Kelly, Hertz, and Mueller26 demon-
strated that alloimmune responses directed against
class I antigens on bronchial epithelium may be
responsible for the development of obliterative airway
disease. Moreover, several groups have shown that the
use of immunosuppression can prevent the develop-
ment of obliterative airway disease.27,28
The present study provides further evidence that OB
is an immune-mediated process. Consistent with the
findings in human and animal studies, our data suggest
that professional APCs may play a central role in the
development of obliterative airway disease.22-24 By
replacing donor-type APCs with recipient-type APCs,
we eliminated direct allorecognition of allopeptides
presented by donor-type APCs and prevented the devel-
opment of obliterative airway disease. Similar to the
B6 and B6(B6) allografts, the B6(C3H) specimens
exhibited evidence of an early inflammatory event at
day 14 that subsided by day 28. However, in contrast to
the B6 and B6(B6) allografts, luminal occlusion of the
B6(C3H) specimens remained minimal at day 28, and
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although flattened and nonciliated, the respiratory
epithelium remained intact. Interestingly, immunosup-
pressive regimens including cyclosporine (INN:
ciclosporin) and sirolimus have been shown to inhibit
the development of obliterative airway disease and
have resulted in similar epithelial changes with mini-
mal luminal occlusion.27,28 The pathogenesis of OB is
thought to involve an early epithelial injury followed
by aberrant epithelial regeneration related to the
alloimmune response. Our findings are consistent with
this paradigm since B6(C3H) tracheas demonstrate
early epithelial injury but undergo a near-normal
process of repair, presumably as a consequence of
reduced immunogenicity of the grafts. Tracheas from
autologously reconstituted B6 mice confirmed that the
lack of obliterative airway disease was not due to the
effects of irradiation or BMT.
Our findings involving the B6I– and the B6II– tracheas
have further demonstrated that “professional” APCs
expressing either MHC class I or class II antigens are
sufficient to trigger the development of obliterative air-
way disease. Previous human and animal studies have
suggested that MHC class I and class II antigens on
bronchial epithelium (a “nonprofessional” APC) are
sufficient to drive the development of OB.8-11,19-21,23,26
In contrast, our data suggest that direct presentation by
the bronchial epithelium or indirect presentation of
donor MHC class I and class II antigens by recipient
APCs is not sufficient to drive the development of
obliterative airway disease.
Increasing evidence suggests that chronic rejection is
mediated by persistent indirect presentation of allopep-
tides. Vella and coworkers29 demonstrated that lympho-
cytes from renal transplant recipients with chronic
rejection had a significant increase in proliferation to
HLA peptides when compared with controls.
Ciubotariu and associates30 showed that the incidence
of cardiac allograft vasculopathy was significantly
higher in patients whose lymphocytes displayed persis-
tent allopeptide reactivity. Last, our laboratory has pre-
viously shown that chimeric rat cardiac allografts bear-
ing recipient-type APCs in a low responder strain
combination survive long term but have severe allo-
graft vasculopathy.17
In our experiments, obliterative airway disease does
not develop in chimeric tracheas in the absence of
donor-type APCs, despite the presence of bronchial
epithelial MHC class I and class II antigens.
Therefore, we believe that obliterative airway disease
is a model of acute rejection, rather than one of chron-
ic rejection. It has been postulated that the vigor of
acute allograft rejection is due to the “unnatural” stim-
ulation of recipient T cells by donor-type APCs (direct
allorecognition). The ability of graft-resident bone
marrow–derived APCs to induce allosensitization was
first demonstrated by Steinmuller.31 Subsequently,
Lechler and Batchelor14 showed that depletion of
donor APCs led to prolonged allograft survival and
that perioperative adoptive transfer of donor-type
APCs restored acute rejection. Recently, our laborato-
ry has reported that donor APC replacement in the
same mouse strain combination alters the tempo and
pathogenesis of cardiac allograft rejection.17 One
caveat is that obliterative airway disease might eventu-
ally develop in chimeric tracheas if subsequent time
points were assessed. However, the inability in our
laboratory to harvest intact chimeric specimens (previ-
ously irradiated) with consistently reliable architecture
beyond 28 days makes it difficult to address this pos-
sibility experimentally.
Even though the fibroproliferative process in oblit-
erative airway disease resembles that found in OB
histologically, the murine heterotopic tracheal trans-
plant model has several limitations. The lesions of
OB are primarily found in the terminal airways in
human beings, whereas the obliterative airway dis-
ease lesion occurs more proximally in the airway. In
addition, the heterotopic tracheal transplant model
depends on neovascularization, in contrast to imme-
diately revascularized orthotopic lung transplant
models. Although this system has been used as a
model of OB, the failure of therapies that effectively
prevent obliterative airway disease to make an impact
on clinical OB further suggests that this model
should be used in studies of acute rejection.
In summary, our study demonstrates that donor-type
APCs are important in the development of obliterative
airway disease in a heterotopic tracheal transplant
model. Furthermore, donor APC expression of either
MHC class I or class II antigens is sufficient to trigger
the development of obliterative airway disease. In
terms of clinical applicability, the concept of APC
depletion to reduce immunogenicity of allografts has
already led to clinical trials with anti-CD45 used in
renal transplantation.32,33 On the basis of these studies,
we would speculate that APC depletion might reduce
the incidence and severity of acute lung rejection.
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